🇺🇸 FDA
Patent

US 9220748

Macrocyclic proline derived HCV serine protease inhibitors

granted A61KA61K38/00A61K38/12

Quick answer

US patent 9220748 (Macrocyclic proline derived HCV serine protease inhibitors) held by Enanta Pharmaceuticals, Inc. expires Mon Dec 24 2035 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Enanta Pharmaceuticals, Inc.
Grant date
Tue Dec 29 2015 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 24 2035 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
15
CPC classes
A61K, A61K38/00, A61K38/12, A61K38/212, A61K38/215